Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2000

View Archived Issues

Progenics expands HIV program with Pharmacopeia, receives SBIR grant

Phase I trial results presented for IDEC-114 antibody in psoriasis

Sanofi-Synthelabo presents overhauled R&D portfolio to financial analysts

New introduction for consensus interferon in major European market

BMS withdraws NDA for UFT and Orzel, plans to resubmit

Clinical testing of solid oral dosage form of heparin commences

Zambon and Sheffield submit IND to FDA for MSI-ipratropium bromide

Bayer licenses anticancer compound from Indena

AVI BioPharma successfully completes phase I trials of Resten-NG

ADIR prepares potent and selective 5-HT1B receptor ligands

New integrin alphav receptor antagonists patented by Merck

Lilly discloses new indole sPLA2 inhibitors

Antimicrobial mutilin derivatives for Gram-positive, Gram-negative and mycoplasmal infections

Aminomethylcarboxylic acid derivatives as inhibitors of glycine transport

Novel anticonvulsants continue as area of focus at SB

Novel class of human 5alpha-reductase inhibitors undergoes evaluation at Yamanouchi

Zyprexa approved in U.S. for bipolar-associated mania

LY-293558, a new glutamate receptor antagonist, evaluated for safety and analgesic efficacy

FDA's ODAC recommends approval of Mylotarg for relapsed AML

European authorities request comparison studies of dexmedetomidine in ICU

ASCPT news: pharmacodynamics of VPA-985 + hydrochlorothiazide in humans

Medinox's NO neutralizer prevents transplant rejection in preclinical study

Health Canada approves AmBisome as antifungal treatment

Tarazepide demonstrates activity as CCK-A antagonist in early clinical trials

Orion licenses deramciclane from Egis and begins phase III program in anxiety

Korean K+ channel activator SKP-450 has promising PK/PD profile in healthy subjects

Phase I results for CVT-510 presented at ACR meeting; CV designs new partial agonist derivative

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...